United States - English - NLM (National Library of Medicine)

b. braun medical inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g in 50 ml - ceftazidime for injection and dextrose injection is indicated for the treatment of lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae , including ampicillin-resistant isolates; klebsiella spp.; enterobacter spp.; proteus mirabilis ; escherichia coli ; serratia spp.; citrobacter spp.; streptococcus pneumoniae ; and staphylococcus aureus (methicillin-susceptible isolates). ceftazidime for injection and dextrose injection is indicated for the treatment of skin and skin-­structure infections caused by pseudomonas aeruginosa ; klebsiella spp.; escherichia coli ; proteus spp., including proteus mirabilis and indole-positive proteus ; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible isolates); and streptococcus pyogenes (group a beta-hemolytic streptococci). ceftazidime for injection and dextrose injection is indicated for the treatment of bacterial septicemia caused by pseudomonas

United States - English - NLM (National Library of Medicine)

sandoz inc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. ceftazidime for injection, usp may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. the dose depends on the severity of the infection and the patient’s condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime f

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 gram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 gram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Malta - English - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 g - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the folowing: severe infections in general (e.g. septicaemia including neonatal sepsis, bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns). respiratory tract (e.g. pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis). severe ear, nose and throat infections (e.g. otitis media, mastoiditis). urinary tract (e.g. acute and chronic pyelonephritis, pyelitis, cystitis - bacterial only; infections associated with bladder and renal stones). skin and soft tissue (e.g. erysipelas abscesses, cellulitis, infected burns and wounds, mastitis). gastrointestinal and abdominal (e.g. intra-abdominal abscesses, enterocolitis). bone and joint (e.g. osteitis, osteomyelitis, septic arthritis, infected burstis).

United States - English - NLM (National Library of Medicine)

hospira, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 6 g - tazicef (ceftazidime for injection, usp) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: tazicef (ceftazidime for injection, usp) may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. tazicef may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of tazicef (ceftazidime) and other antibacterial drugs,

United States - English - NLM (National Library of Medicine)

hospira, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g - tazicef (ceftazidime for injection, usp) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: tazicef (ceftazidime for injection, usp) may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. tazicef (ceftazidime for injection, usp) may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of tazicef (ceftazidime